Crohn's Disease and Colitis Trial, Recruiting NCT06971627 Sponsor: Istanbul University - Cerrahpasa Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT06971627
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who can read and write in Turkish
  • People who have been diagnosed with inflammatory bowel disease (IBD) for at least 6 months
  • People whose IBD is currently in remission (meaning the disease is well-controlled and not causing active symptoms, based on specific medical scoring tools — confirm with trial site)
  • People who own and are able to use a smartphone
  • People who have access to an online messaging app (such as WhatsApp) and a working email address
  • People who are able to download and use a video call app on a phone or computer (such as Zoom)
  • People who are willing to take part in the study voluntarily

Who may not be able to join:

  • People who have been diagnosed with a psychiatric or cognitive (thinking or memory-related) disorder
  • People who have any condition that affects their ability to communicate
  • People who are currently pregnant
  • People who are receiving treatment given through an infusion (medication delivered directly into the bloodstream via a drip)
  • People who have a serious, advanced long-term illness

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kimya Kılıçaslan, PhD Candidate, Istanbul University - Cerrahpasa Institute of Graudate Studies

Phone: +90 535 083 45 53

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Istanbul University - Cerrahpasa
Registry
ClinicalTrials.gov
Start date
20 April 2024
Est. completion
20 July 2024

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Change in Medication Adherence Report Scale (MARS) scores

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov